News & Events

Date Title and Summary Additional Formats
Toggle Summary Vertex Reports Second-Quarter 2018 Financial Results
-Second-quarter 2018 total CF product revenues of $750 million , a 46% increase compared to $514 million in the second quarter of 2017- -Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&D and SG&A expense
View HTML
Toggle Summary Vertex Reports First-Quarter 2018 Financial Results
-First-quarter 2018 total CF product revenues of $638 million , a 33% increase compared to $481 million in the first quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.65 to $2.80 billion and combined non-GAAP R&D and SG&A expense guidance of $1.50 to $1.55
View HTML
Toggle Summary Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results
-Total 2017 CF product revenues of $2.17 billion , a 29% increase compared to $1.68 billion in 2016; 2017 KALYDECO revenues of $845 million and 2017 ORKAMBI revenues of $1.32 billion - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated
View HTML
Toggle Summary Vertex Reports Third-Quarter 2017 Financial Results
-Third-quarter 2017 cystic fibrosis product revenues of $550 million , up 34% versus Q3 2016; $336 million for ORKAMBI and $213 million for KALYDECO- -Company increases total 2017 CF product revenue guidance to $2.10 to $2.15 billion ; increases ORKAMBI revenue guidance to $1.29 to $1.32 billion
View HTML
Toggle Summary Vertex Reports Second-Quarter 2017 Financial Results
-Second-quarter 2017 cystic fibrosis product revenues of $514 million ; $324 million for ORKAMBI and $190 million for KALYDECO- -Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidance for combined GAAP and non-GAAP R&D and SG&A expenses- -Pipeline of
View HTML
Toggle Summary Vertex Reports First-Quarter 2017 Financial Results
-First-quarter 2017 cystic fibrosis product revenues of $481 million ; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million -
View HTML
Toggle Summary Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results
-2016 total CF product revenues of $1.68 billion compared to $982 million in 2015; $980 million for ORKAMBI and $703 million for KALYDECO- -Fourth-quarter 2016 total CF product revenues of $454 million ; $277 million for ORKAMBI and $177 million for KALYDECO- -Company reiterates 2017 financial
View HTML
Toggle Summary Vertex Reports Third Quarter 2016 Financial Results
-Third quarter 2016 cystic fibrosis product revenues of $410 million ; $234 million for ORKAMBI ® (lumacaftor/ivacaftor) and $176 million for KALYDECO ® (ivacaftor)- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the
View HTML
Toggle Summary Vertex Reports Second Quarter 2016 Financial Results
-Second quarter 2016 cystic fibrosis product revenues of $426 million ; $245 million for ORKAMBI ® (lumacaftor/ivacaftor) and $180 million for KALYDECO ® (ivacaftor)- -Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705
View HTML
Toggle Summary Vertex Reports First Quarter 2016 Financial Results
-First quarter 2016 cystic fibrosis product revenues of $394 million ; $223 million for ORKAMBI ® (lumacaftor/ivacaftor) and $171 million for KALYDECO ® (ivacaftor)- -Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion ; increases 2016 guidance for KALYDECO product revenues
View HTML
Toggle Summary Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
-Full-year 2015 total non-GAAP revenues of $1.01 billion , including net product revenues of $351 million for ORKAMBI ® (lumacaftor/ivacaftor) and $632 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex reiterates 2016 financial guidance for KALYDECO net product revenues of $670 to $690
View HTML
Toggle Summary Vertex Reports Third Quarter 2015 Financial Results
-Third quarter 2015 revenues of $310 million , including net product revenues of $131 million for ORKAMBI ® (lumacaftor/ivacaftor) and $166 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for 2015 KALYDECO net revenues; now expects KALYDECO revenues of $605 to $620
View HTML
Toggle Summary Vertex Reports Second Quarter 2015 Financial Results
-Second quarter 2015 total revenues of $166 million , including net product revenues of approximately $155 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million - -ORKAMBI™
View HTML
Toggle Summary Vertex Reports First Quarter 2015 Financial Results
-First quarter 2015 total revenues of $139 million , including net product revenues of $130 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals
View HTML
Toggle Summary Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015
-Full-year 2014 total revenues of $580 million , including net product revenues of $464 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.4 billion on December 31, 2014 - -Company expects total 2015 KALYDECO net revenues of $560 to $580
View HTML
Toggle Summary Vertex Reports Third Quarter 2014 Financial Results
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014 . Vertex reported total third quarter 2014 GAAP revenues of $179 million , including revenues of $127 million from KALYDECO ®
View HTML
Toggle Summary Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2014. Vertex reported total second quarter 2014 revenues of $138 million , including revenues of $113 million from KALYDECO ® (ivacaftor).
View HTML
Toggle Summary Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014
-Full-year 2013 total revenues of $1.21 billion , including net product revenues of $371.3 million for KALYDECO in cystic fibrosis and $466.3 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.47 billion on December 31, 2013- -Company expects
View HTML
Toggle Summary Vertex Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014
-Third quarter 2013 total revenues of $222 million , including net product revenues of $101 million for KALYDECO in cystic fibrosis and $86 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.42 billion on September 30, 2013- -Company reduces
View HTML
Toggle Summary Vertex Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs
-Second quarter 2013 total revenues of $311 million , including net product revenues of $99 million for KALYDECO in cystic fibrosis and $156 million for INCIVEK in hepatitis C; cash position of approximately $1.43 billion on June 30, 2013 - -Data from Phase 3 study of ivacaftor monotherapy support
View HTML
Toggle Summary Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C
-First quarter 2013 total revenues of $328 million , including net product revenues of $206 million for INCIVEK in hepatitis C and $62 million for KALYDECO in cystic fibrosis- -Cystic fibrosis: Enrollment ongoing in Phase 3 program for VX-809 in combination with ivacaftor for people with two copies
View HTML
Toggle Summary Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs
-2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -Full-year 2012 revenues of $1.53 billion , including net product revenues of $1.16 billion for INCIVEK in hepatitis C and $171.6 million for KALYDECO in cystic fibrosis- -Company ends 2012
View HTML
Toggle Summary Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs
-Third quarter 2012 total revenues of $336 million , including third quarter 2012 net product revenues of approximately $254 million for INCIVEK in hepatitis C and $49 million for KALYDECO in cystic fibrosis- -Cystic Fibrosis: Three ongoing Phase 3 label expansion studies for ivacaftor monotherapy;
View HTML
Toggle Summary Vertex Reports Second Quarter 2012 Financial Results and Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis
-Second quarter 2012 total revenues of $418 million , including second quarter 2012 net product revenues of approximately $328 million for INCIVEK in hepatitis C and $46 million for KALYDECO in cystic fibrosis; company revises financial guidance for full-year 2012 INCIVEK net revenues- -Cystic
View HTML
Toggle Summary Vertex Reports First Quarter 2012 Financial Results and Provides Update on Launch of KALYDECO™
-Approximately 600 people with cystic fibrosis have started treatment with KALYDECO since approval on January 31 - -Multiple ongoing clinical trials to generate data beginning in second quarter, including study of KALYDECO combined with VX-809 in cystic fibrosis and first data for Alios nucleotides
View HTML
Toggle Summary Vertex Reports Fourth Quarter and Full-Year 2011 Financial Results
-Successful launch of INCIVEK (telaprevir) for hepatitis C and recent approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for continued growth, earnings and cashflow- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated
View HTML
Toggle Summary Vertex Reports Profitable Third Quarter and Provides Updates on INCIVEKTM (telaprevir) Launch and Medicines in Development
- $420 million in net product revenues for INCIVEK for the first full quarter since launch- -Continued strength in launch of INCIVEK for hepatitis C; submissions of KALYDECO TM (VX-770, ivacaftor) approval applications complete- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals
View HTML
Toggle Summary Vertex Reports Second Quarter 2011 Financial Results and Provides Updates on Launch of INCIVEKTM (telaprevir) and Development Programs
-Quarter highlighted by approval and launch of INCIVEK TM for hepatitis C and completion of VX-770 Phase 3 program in cystic fibrosis- -Continued progress in advancing new combinations of medicines for the future treatment of hepatitis C and cystic fibrosis- CAMBRIDGE, Mass.
View HTML
Toggle Summary Vertex Reports First Quarter 2011 Financial Results and Reviews Milestones for Key Development Programs
-Hepatitis C: FDA decision on NDA for INCIVEK TM (telaprevir) expected this month- -Cystic Fibrosis: Phase 3 program for VX-770 supports applications for approval in U.S. and E.U., with NDA and MAA planned for second half of 2011- -Financial: Vertex enters second quarter with more than $820 million
View HTML
Toggle Summary Vertex Reports 2010 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
  -Hepatitis C: Regulatory agencies in U.S., Europe and Canada to provide accelerated reviews of telaprevir applications- -Cystic Fibrosis: First Phase 3 registration data for VX-770 expected in first quarter 2011; potential regulatory submissions in the U.S. and E.U.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights Progress in Hepatitis C and Cystic Fibrosis Development Programs
<i>-Hepatitis C:</i> <i>New Drug Application submission for telaprevir on track for fourth quarter 2010-</i> <br /> <i>-Cystic Fibrosis:</i> <i>Phase 3 registration program ongoing for VX-770-</i> <br /> <i>-Pipeline:</i> <i>Ongoing proof-of-concept clinical trials in hepatitis C, cystic fibrosis, epilepsy and rheumatoid arthritis-</i> <br /> <i>-Financial:</i> <i>Company ends third quarter with a cash position of $1.2 billion-</i> <br />
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress
<i>-Hepatitis C: Rolling submission of New Drug Application underway; data from second pivotal Phase 3 trial - REALIZE - expected in the third quarter of 2010-</i> <br /> <i>-Cystic Fibrosis: Phase 3 registration program for VX-770 fully enrolled; data expected in first half of 2011-</i> <br /> <i>-Financial: Vertex ends second quarter with cash position of approximately $980 million-</i> <br />
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress
<i>-HCV: Rolling submission of New Drug Application for telaprevir expected to begin in summer of 2010; first Phase 3 SVR data expected in second quarter 2010 from ADVANCE trial-</i> <br /> <i>-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of Phase 3 registration program for VX-770; data expected in first half of 2011-</i> <br /> <i>-Pipeline: Multiple ongoing or planned proof-of-concept clinical trials with compounds for rheumatoid arthritis and epilepsy and with novel combination regimens for HCV and CF-</i> <br /> <i>-Financial: Vertex ends first quarter with cash position of approximately $1.1 billion-</i> <br />
View HTML
Toggle Summary Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
<i>-HCV: New Drug Application planned for telaprevir in second half of 2010; increasing investment in commercialization and launch preparedness activities-</i> <br /> <i>-CF: Development progress with two compounds in orphan disease of cystic fibrosis; combination trial planned with VX-770 and VX-809 based on Phase 2 data for VX-809-</i> <br /> <i>-Pipeline: Proof-of-concept clinical trials planned for 2010 with novel combination regimens for hepatitis C and cystic fibrosis and with compounds for rheumatoid arthritis and epilepsy-</i> <br /> <i>-Financial: Vertex enters 2010 with approximately $1.3 billion in cash, cash equivalents and marketable securities and approximately $32 million in outstanding 2013 convertible debt; 2010 investment to support long-term business objectives-</i> <br />
View HTML